Renal Cell Carcinoma: Update on Clinical Data, Trials, and Guidance for Community Practice

Renal Cell Carcinoma: Update on Clinical Data, Trials, and Guidance for Community Practice

Monday, January 30, 2023
Webinar -- 4:00 PM MT
https://cmmglobal1.webex.com/cmmglobal1/onstage/g.php?MTID=e745dd6005dc65dfe1e432d72fd54d378 password: 6610

Agenda

  • Program Overview
  • Perplexities in non-metastatic RCC at Initial Diagnosis
  • Immuno-Oncology Combinations in First-Line Metastatic RCC
  • Case Examples with Discussion
    • Planning Optimal First-Line Treatment for Individual patients with Advanced or Metastatic RCC
    • Optimal Treatment for Patients with Progressive RCC after 1 or More Previous Lines of Therapy
  • Management of Adverse Events Associated with Immunotherapy-Based Combinations for Advanced RCC
  • Looking Ahead: Ongoing clinical trials
  • Closing Remarks and Question and Answer Session

Faculty

Faculty
Elizabeth R. Plimack, MD, MS

Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging therapies for treatment of RCC.

Target Audience
This interprofessional training program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with RCC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Appraise clinical data on systemic treatment approaches for patients with operable, advanced or metastatic RCC
  • Identify patients most likely to benefit from targeted and/or immune checkpoint inhibitor–based combination therapies based on risk and biomarker assessment, along with patient medical and treatment history
  • Plan optimal first-line treatment for individual patients with advanced or metastatic RCC, taking into consideration targeted and immune checkpoint inhibitor combination options, available clinical evidence, expert recommendations, and patient preferences
  • Apply guideline-directed therapeutic strategies to optimize the sequence of therapies to provide the best outcome to patients with RCC
  • Manage specific disease-related complications or adverse events associated with currently approved monotherapies and therapy combinations for advanced RCC
  • Select patients who may benefit from ongoing clinical trials based on tumor characteristics, previous treatment, and patient characteristics and preferences

Accreditation

YOUR CONFIRMATION

Renal Cell Carcinoma: Update on Clinical Data, Trials, and Guidance for Community Practice

On behalf of Clinical Care Options, LLC, we are pleased to confirm your registration for the upcoming event.

Date:        Monday, January 30, 2023
Time:        4:00 PM - 5:00 PM MT
URL:          https://cmmglobal1.webex.com/cmmglobal1/onstage/g.php?MTID=e745dd6005dc65dfe1e432d72fd54d378                         Password: 6610

Agenda

    • Program Overview
    • Perplexities in non-metastatic RCC at Initial Diagnosis
    • Immuno-Oncology Combinations in First-Line Metastatic RCC
    • Case Examples with Discussion
      • Planning Optimal First-Line Treatment for Individual patients with Advanced or Metastatic RCC
      • Optimal Treatment for Patients with Progressive RCC after 1 or More Previous Lines of Therapy
    • Management of Adverse Events Associated with Immunotherapy-Based Combinations for Advanced RCC
    • Looking Ahead: Ongoing clinical trials
    • Closing Remarks and Question and Answer Session


Complete program information regarding faculty, agenda, and CME credit is available online at: events.clinicaloptions.com.

Questions? Please email customersupport@cealliance.com

                                                                              
Provided by Clinical Care Options, LLC.
Supported by an educational grant from Janssen Biotech, Inc.
administered by Janssen Scientific Affairs, LLC.
Copyright 2023 Clinical Care Options, LLC. All rights reserved.
Clinical Care Options, LLC 12001 Sunrise Valley Drive, Suite 300, Reston, VA 20191